7 completed, 2 recruiting, 2 terminated, 1 suspended. 12 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Completed 7, Recruiting 2, Terminated 2, Suspended 1 |
| Phase 2 | 1 | Completed 1 |
Follow Acromegaly: new trials by email Literature Review of Acromegaly trials Research Report on Acromegaly
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1 Study to Evaluate the Relative Bioavailability of Octreotide Acetate Tablets(T25) Compared to MYCAPSSA® and The Food Effect on Pharmacokinetics Of Octreotide Acetate Tablets(T25) T25-Fast, Mycapssa, T25-Fed - Acromegaly | Phase 1 | Completed | Triastek (Shanghai) Limited | 18 | 2026-06-25 | 2026-09-16 |
| A Phase 1 Clinical Trial of NTQ6179 Tablets in Healthy Volunteers NTQ6179, NTQ6179 placebo - Acromegaly | Phase 1 | Recruiting | Nanjing Chia-tai Tianqing Pharmaceutical | 56 | 2026-04-23 | 2026-11-03 |
| Study of MAR002 in Healthy Men MAR002, Placebo - Acromegaly | Phase 1 | Recruiting | Marea Therapeutics | 45 | 2025-08-11 | 2026-01-12 |
| A Phase 1 Study of TE-8214 Solution in Healthy Volunteers TE-8214 - SAD, Placebo - Acromegaly | Phase 1 | Completed | Immunwork, Inc. | 32 | 2024-06-18 | 2025-05-20 |
| A Single-dose Study of Octreotide Injection in Healthy Adult Subjects SYHX2008 injection, Octreotide Acetate Microspheres for Injection injection, Sandostatin ® injection - Acromegaly | Phase 1 | Completed | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 56 | 2023-03-02 | 2023-10-10 |
| A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Debio 4126, Sandostatin LAR, Somatuline ATG - Acromegaly, GEP-NET | Phase 1 | Terminated | Debiopharm International SA | 19 | 2022-05-18 | 2025-11-17 |
| Vitamin D Metabolism in Patients With Endocrine Disorders Cholecalciferol 15000 UNT/ML Oral Solution - Pituitary ACTH Hypersecretion, Acromegaly | Phase 1 | Completed | Endocrinology Research Centre, Moscow | 261 | 2019-04-16 | 2022-08-11 |
| Single-dose Study to Evaluate the Absolute Bioavailability and Mass Balance of ONO-5788 ONO-5788, [14C]-ONO-5788 - Acromegaly | Phase 1 | Completed | Ono Pharmaceutical Co., Ltd. | 12 | 2019-02-27 | 2019-11-07 |
| A Four-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-5788 in Healthy Adult Volunteers ONO-5788, ONO-5788 Placebo, Octreotide - Acromegaly | Phase 1 | Terminated | Ono Pharmaceutical Co., Ltd. | 76 | 2018-06-07 | 2019-06-05 |
| Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly Lanreotide PRF - Acromegaly | Phase 1 / Phase 2 | Completed | Ipsen | 28 | 2015-03-01 | 2019-04-25 |
| Pharmacodynamics Of Product Octreotide Acetate Lar 30 Mg Compared To Product Sandostatin LAR ® Octreotide acetate LAR, Sandostatin LAR ® (octreotide acetate LAR) 30 MG - Acromegaly | Phase 1 | Suspended | Azidus Brasil | 16 | 2010-03-01 | 2022-11-03 |
| Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease Pasireotide - Carcinoid Tumor, Acromegaly | Phase 1 | Completed | Novartis Pharmaceuticals | 85 | 2006-06-01 | 2020-12-21 |
Carcinoid Tumor (1) · Diabetes Mellitus, Type 1 (1) · Gastro-enteropancreatic neuroendocrine tumor (1) · Hyperparathyroidism, Primary (1) · Pituitary ACTH Hypersecretion (1) · Vitamin D Deficiency (1)
Bone Diseases (12) · Bone Diseases, Endocrine (12) · Brain Diseases (12) · Central Nervous System Diseases (12) · Endocrine System Diseases (12) · Hyperpituitarism (12) · Hypothalamic Diseases (12) · Musculoskeletal Diseases (12) · Nervous System Diseases (12) · Pituitary Diseases (12) · Adenocarcinoma (1) · Autoimmune Diseases (1) · Avitaminosis (1) · Carcinoma (1) · Deficiency Diseases (1)
Octreotide (4) · lanreotide (2) · Injections (1) · pasireotide (1)
Ono Pharmaceutical Co., Ltd. (2) · Azidus Brasil (1) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (1) · Debiopharm International SA (1) · Endocrinology Research Centre, Moscow (1) · Immunwork, Inc. (1) · Ipsen (1) · Marea Therapeutics (1) · Nanjing Chia-tai Tianqing Pharmaceutical (1) · Novartis Pharmaceuticals (1) · Triastek (Shanghai) Limited (1)
China (3) · Germany (3) · Netherlands (3) · United States (3) · Belgium (2) · France (2) · Italy (2) · Poland (2) · Russia (2) · Spain (2) · United Kingdom (2) · Australia (1) · Brazil (1) · Canada (1) · Czechia (1)
Jan Jaap van Lier, MD (1) · Liudmila Rozhinskaya, MD, PhD (1) · Shan NA Jing, PhD (1) · Terry O'Reilly, MD (1) · Yang NA Lin, PhD (1)
PMID 24800725, PMID 34664531, PMID 35138562, PMID 42712757
2005 (1), 2014 (1)